|Bid||95.99 x 1200|
|Ask||96.32 x 1100|
|Day's range||95.04 - 96.25|
|52-week range||58.59 - 97.07|
|Beta (3Y monthly)||2.01|
|PE ratio (TTM)||14.66|
|Earnings date||24 Jul 2019 - 29 Jul 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||97.00|
For these mental hacks, David Gardner tapped the wisdom of four authors and one alien hive mind. For the stocks, he looked to the Information Age for inspiration.
Celgene Corporation (CELG) and the Multiple Sclerosis Association of America (MSAA) today announced the launch of a new campaign, MS MindShift: A New View of MS, a national initiative that provides new perspective on multiple sclerosis (MS). The campaign aims to educate about the critical role the brain plays in the disease and what people living with MS can do to keep their brain as healthy as possible, for as long as possible. To bring this new perspective on MS closer to the community, the campaign will host engaging, educational events in various cities.
A stormy honeymoon could be in the offing following the biggest pharmaceutical acquisition in history, according to one analyst.
Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.
The European Commission has approved two of Celgene’s IMiD®-based combination regimens:
Presentations include innovative cancer research, including novel CAR T technology, as well as key disease areas, including myelofibrosis and multiple myeloma
Celgene plans to submit sNDA by end of 2019
The company issued senior unsecured bonds in nine parts, according to data compiled by Bloomberg. Bristol-Myers said it would take on $32 billion of new debt in addition to $20 billion of existing Celgene obligations to complete what will be the largest pharmaceutical merger in history, according to a January investor presentation. Bristol-Myers is leading the charge for what’s expected to be a heavy supply month in corporate bonds.
In January, Bristol-Myers said it planned to buy Celgene, and shareholders approved the deal in April. Shareholder Wellington Management, which rarely publicly expresses opinions about transactions, opposed the deal, as did activist investor Starboard Value. The company is selling $19 billion in bonds across nine tranches maturing in 1½ to 30 years.
Celgene Corporation (CELG) today announced the results of a post-hoc analysis of data from the Phase 3 RADIANCE™ Part B trial showing that ozanimod reduced cortical grey matter volume loss versus first-line treatment, Avonex® (interferon beta-1a), in adults with relapsing multiple sclerosis (RMS) across all age groups, including patients ages 18 to 25. The analysis will be presented at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia, May 4-10, 2019.
Barclays analyst Geoff Meacham thinks that the companies’ combined drug pipelines make Bristol-Myers a force to watch in the years ahead.
Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down.